Olema Pharmaceuticals, Inc. today announced that management will participate in two upcoming investor conferences in November.
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that management will participate in two upcoming investor conferences in November.
Details for the company’s participation are as follows:
- Event: Jefferies London Healthcare Conference
Date: Tuesday, November 16, 2021
Time: 5:00 p.m. GMT (12:00 p.m. ET / 9:00 a.m. PT)
Format: Live Fireside Chat - Event: 4th Annual Evercore ISI HealthCONx Conference
Date: Tuesday, November 30, 2021
Time: 11:45 a.m. ET (8:45 a.m. PT)
Format: Live Fireside Chat
Live webcasts of these presentations may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for 14 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is based in San Francisco and has operations in Cambridge, Massachusetts.
Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com
